MEI Pharma, Inc. (MEIP)

NASDAQ: MEIP · IEX Real-Time Price · USD
3.275
-0.035 (-1.06%)
Apr 19, 2024, 1:53 PM EDT - Market open
-1.06%
Market Cap 21.82M
Revenue (ttm) 72.65M
Net Income (ttm) 19.84M
Shares Out 6.66M
EPS (ttm) 2.97
PE Ratio 1.09
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 25,315
Open 3.275
Previous Close 3.310
Day's Range 3.210 - 3.290
52-Week Range 3.200 - 7.970
Beta 0.64
Analysts Buy
Price Target 43.50 (+1,228.24%)
Earnings Date May 9, 2024

About MEIP

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosph... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 19, 2003
Employees 46
Stock Exchange NASDAQ
Ticker Symbol MEIP
Full Company Profile

Financial Performance

In 2023, MEI Pharma's revenue was $48.82 million, an increase of 19.95% compared to the previous year's $40.70 million. Losses were -$31.84 million, -41.53% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for MEIP stock is "Buy." The 12-month stock price forecast is $43.5, which is an increase of 1,228.24% from the latest price.

Price Target
$43.5
(1,228.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...

8 days ago - Business Wire

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...

8 days ago - Business Wire

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...

9 days ago - Business Wire

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...

24 days ago - Business Wire

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors' and officers' possible violation...

2 months ago - Business Wire

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...

2 months ago - Business Wire

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...

3 months ago - Business Wire

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...

4 months ago - Business Wire

MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...

5 months ago - Business Wire

MEI Pharma to Present at the Stifel 2023 Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will participate in the Stifel 20...

5 months ago - Business Wire

MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that pursuant to the...

5 months ago - Business Wire

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that an abstract highlighting clinic...

6 months ago - Business Wire

MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital

SAN DIEGO & TORONTO & SAN FRANCISCO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) and Anson Funds and Cable Car Capital (“Anson and Cable Car”) today announced that they have enter...

6 months ago - Business Wire

MEI Pharma Recommends Stockholders Not to Consent

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that it has filed a definitive consent revocation statement with the U.S. Securities and Exchange Commission...

6 months ago - Business Wire

MEI Pharma Adopts Limited-Duration Stockholder Rights Plan

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its Board of Directors has unan...

7 months ago - Business Wire

MEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic Actions

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “MEI” or “the Company”) today issued the following statement in response to the consent solicitation initiated by a group led by Anson ...

7 months ago - Business Wire

MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended Jun...

7 months ago - Business Wire

MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 20...

7 months ago - Business Wire

MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today issued the following statement regarding the nomination of three director candidates by Anson Advisors Inc. and Cable ...

7 months ago - Business Wire

MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the dosing of the first patient in a...

8 months ago - Business Wire

MEI Pharma Announces Results of Special Meeting of Stockholders

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that, based on a count of the votes cast at the Company's Special Meeting of Stockholders, MEI, by a narrow ...

9 months ago - Business Wire

MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinit...

9 months ago - Business Wire

MEI Pharma Responds to Anson and Cable Car

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today issued the following statement in response to the Consent Solicitation launched by Anson Advisors Inc. and Cable Car C...

9 months ago - Business Wire

MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharma...

9 months ago - Business Wire

MEI Pharma Postpones Special Meeting of Shareholders

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that it has postponed its special meeting in connection with the proposed transaction with Infinity Pharmace...

10 months ago - Business Wire